Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shenghui Granules is a Traditional Chinese Medicine (TCM) formulation developed by the Hubei University of Chinese Medicine. It is currently being investigated for the treatment of mild cognitive impairment (MCI) associated with Alzheimer's disease. As a multi-herbal botanical product, it is intended to improve cognitive function and safety in patients, with clinical trials exploring its potential mechanisms of action in neuroprotection or cognitive enhancement. The formulation is typically administered orally in granule form.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shenghui Granules.